Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database
BackgroundCancer remains one of the leading is associated with of death globally. This study analyzed adverse drug event (ADE) signals and potential factors associated with reporting in ipilimumab and nivolumab-treated cancer data from the Food and Drug Administration’s (FDA) Adverse Event Reporting...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2026-06-01
|
| シリーズ: | Frontiers in Endocrinology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fendo.2026.1786504/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|